Nippon India Banking & Financial Services Fund vs Nippon India Pharma Fund
Direct Plan, Growth option · Data as on 30-10-2026
Nippon India Banking & Financial Services Fund is a Sectoral fund and Nippon India Pharma Fund is a Sectoral fund. In the 3 years to 30-10-2026, Nippon India Banking & Financial Services Fund (Direct) returned 9.9% a year and Nippon India Pharma Fund (Direct) returned 18.6% a year. Nippon India Banking & Financial Services Fund charges 1.11% a year and Nippon India Pharma Fund 0.99% (Direct plans). Their portfolios overlap 0.0%: they hold 0 of the same securities.
Nippon India Banking & Financial Services Fund
Sectoral
- 3 year return
- 9.9%
- Expense ratio
- 1.11%
- NAV
- ₹653.74
Nippon India Pharma Fund
Sectoral
- 3 year return
- 18.6%
- Expense ratio
- 0.99%
- NAV
- ₹625.46
Which is better, Nippon India Banking & Financial Services or Nippon India Pharma? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Nippon India Pharma returned more over 5 years: 14.2% a year against 10.8%.
- Nippon India Pharma returned more over 3 years: 18.6% a year against 9.9%.
- Nippon India Pharma costs less: 0.99% a year against 1.11% (Direct plans).
- Nippon India Pharma swung less over 3 years: a standard deviation of 13.0% a year against 15.3%.
- Nippon India Pharma fell less in its worst fall since 02-01-2013: −24.0% against −50.6%.
- Nippon India Banking & Financial Services holds more in large companies: 58.5% of the fund in large caps against 29.7%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹7,367 Cr.
- Their portfolios overlap 0.0%: 0 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Nippon India Banking & Financial Services Fund | Nippon India Pharma Fund |
|---|---|---|
| Fund house | Nippon India Mutual Fund | Nippon India Mutual Fund |
| Category | Sectoral | Sectoral |
| AUM | ₹7,367 Cr (30-09-2026) | ₹9,166 Cr (30-09-2026) |
| NAV | ₹653.74 (Direct) | ₹625.46 (Direct) |
| Expense ratio (Direct) | 1.11% | 0.99% |
| Expense ratio (Regular) | 1.93% | 1.85% |
| Riskometer | Very High | Very High |
| Benchmark | Nifty Financial Services TRI | BSE Healthcare TRI |
| Launch date | 26-05-2003 | 05-06-2004 |
| Minimum investment | ₹5,000 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Vinay Sharma, Bhavik Dave | Sailesh Raj Bhan |
| Exit load | Exit load of 1%, if redeemed within 1 month. | Exit load of 1% if redeemed within 1 month. |
Nippon India Banking & Financial Services vs Nippon India Pharma: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Nippon India Banking & Financial Services Fund (Direct) | −2.63% | −7.11% | −4.51% | −8.11% | +9.87% | +10.82% | +12.21% |
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | +15.61% | +14.51% | +14.77% |
Category average: the average of the 20 Sectoral funds, same plan type.
Nippon India Banking & Financial Services vs Nippon India Pharma: Year-wise Returns
| Year | Banking & Financial ServicesNippon India Banking & Financial Services | PharmaNippon India Pharma |
|---|---|---|
| 2026to date | −9.76% | +9.76% |
| 2025 | +18.39% | −2.46% |
| 2024 | +11.25% | +35.26% |
| 2023 | +25.11% | +40.36% |
| 2022 | +21.75% | −9.06% |
| 2021 | +30.66% | +25.12% |
Nippon India Banking & Financial Services vs Nippon India Pharma: Rolling Returns
Every holding period of both funds, against Nifty Financial Services TRI, the benchmark of Nippon India Banking & Financial Services Fund
Rolling returns
Every 3-year holding period, 2,666 of them, one for each trading day from 04-01-2016 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Nippon India Banking & Financial Services Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Financial Services TRI
to
Nov 2016Sept 2015
to
Sept 2018Jul 2017
to
Jul 2020May 2019
to
May 2022Mar 2021
to
Mar 2024Dec 2022
to
Dec 2025
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nippon India Banking & Financial Services | 7.2 | 3.4 | 10.6 | 21.2 | 28.8 | 15.8 | 13.1 | 15.7% | 16.2% | −14.2% | 42.6% | 62% |
| Nippon India Pharma | 1.4 | 18.1 | 5.5 | 4.5 | 21.3 | 28.4 | 20.8 | 17.2% | 19.9% | −1.3% | 32.2% | 64% |
| Nifty Financial Services TRI | 0.4 | 4.4 | 12.2 | 36.6 | 25.9 | 15.9 | 4.5 | 15.1% | 14.5% | −2.1% | 31.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is Nifty Financial Services TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 02-01-2013. Past returns do not promise future returns.
Nippon India Banking & Financial Services vs Nippon India Pharma: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 02-01-2013 to 30-10-2026: 166 instalments, ₹16,60,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Nippon India Banking & Financial ServicesNippon India Banking & Financial Services Fund (Direct) | ₹16,60,000 | ₹44,24,659 | ₹27,64,659 | 13.2% |
| Nippon India PharmaNippon India Pharma Fund (Direct) | ₹16,60,000 | ₹58,91,410 | ₹42,31,410 | 16.8% |
Nippon India Banking & Financial ServicesNippon India Banking & Financial Services Fund (Direct)
Nippon India PharmaNippon India Pharma Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Nippon India Banking & Financial Services vs Nippon India Pharma: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Nippon India Banking & Financial Services Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | −8.11% | +9.05% |
| Standard deviation | 16.74% | 12.27% |
| Sharpe ratio | -0.80 | 0.31 |
| Sortino ratio | -1.09 | 0.45 |
| Maximum drawdown | −16.7% (31-03-2026) | −9.6% (23-10-2026) |
| Beta | 0.92 | 0.87 |
| Alpha | −0.32% | −2.40% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Nippon India Banking & Financial Services Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +9.87% | +18.56% |
| Standard deviation | 15.26% | 12.96% |
| Sharpe ratio | 0.25 | 0.97 |
| Sortino ratio | 0.35 | 1.39 |
| Maximum drawdown | −16.7% (31-03-2026) | −14.7% (28-02-2025) |
| Beta | 0.90 | 0.88 |
| Alpha | +0.46% | −2.50% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Nippon India Banking & Financial Services Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +10.82% | +14.19% |
| Standard deviation | 16.09% | 12.88% |
| Sharpe ratio | 0.31 | 0.65 |
| Sortino ratio | 0.43 | 0.93 |
| Maximum drawdown | −17.4% (20-06-2022) | −18.7% (17-06-2022) |
| Beta | 0.91 | 0.89 |
| Alpha | +4.26% | −0.35% |
From daily NAVs, 29-10-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Nippon India Banking & Financial Services Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +12.85% | +17.18% |
| Standard deviation | 20.73% | 15.19% |
| Sharpe ratio | 0.33 | 0.73 |
| Sortino ratio | 0.45 | 1.06 |
| Maximum drawdown | −50.6% (22-05-2020) | −24.0% (29-05-2017) |
| Beta | 0.93 | 0.85 |
| Alpha | +0.47% | +3.72% |
From daily NAVs, 02-01-2013 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Nippon India Banking & Financial Services Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Financial Services TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Nippon India Banking & Financial Services Fund (Direct) | −50.6% | 27-05-2019 | 22-05-2020 | 08-02-2021 | 9 months | −12.1% |
| Nippon India Pharma Fund (Direct) | −24.0% | 30-10-2015 | 29-05-2017 | 17-08-2018 | 15 months | −4.3% |
| Nifty Financial Services TRI | −43.5% | 02-01-2020 | 23-03-2020 | 15-12-2020 | 9 months | −12.4% |
From daily values since 02-01-2013, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Nippon India Banking & Financial Services Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Financial Services TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Nippon India Banking & Financial Services Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Financial Services TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 5-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Nippon India Banking & Financial Services Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Financial Services TRI
Against Nifty Financial Services TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Nippon India Banking & Financial Services Fund (Direct) | 104% | 105% | 7.70% |
| Nippon India Pharma Fund (Direct) | 55% | 7% | 22.89% |
From month-end values since 02-01-2013. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Nippon India Banking & Financial Services vs Nippon India Pharma: Portfolio Overlap
From each fund's latest monthly portfolio: Nippon India Banking & Financial Services Fund, September 2026; Nippon India Pharma Fund, September 2026
Holdings in common
- Overlap
- 0.0%
- Held by both
- 0
- Only in Nippon India Banking & Financial Services
- 33
- Only in Nippon India Pharma
- 36
Overlap: for each holding both funds own, the smaller of its two weights, added up. 0.0% means 0.0% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Nippon India Banking & Financial Services Fund
| Security | % of fund |
|---|---|
| HDFC Bank Limited | 15.76% |
| ICICI Bank Limited | 13.26% |
| Axis Bank Limited | 9.00% |
| State Bank of India | 4.97% |
| Kotak Mahindra Bank Limited | 4.06% |
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| Sun Pharmaceutical Industries Limited | 11.71% |
| Divi's Laboratories Limited | 7.10% |
| Lupin Limited | 6.17% |
| Cipla Limited | 6.01% |
| Dr. Reddy's Laboratories Limited | 5.45% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Nippon India Banking & Financial Services | Nippon India Pharma |
|---|---|---|
| Equity | 99.2% | 97.3% |
| Debt | 0.0% | 0.0% |
| Cash and others | 0.8% | 2.7% |
Market cap of stocks
| Market cap | Nippon India Banking & Financial Services | Nippon India Pharma |
|---|---|---|
| Large Cap | 58.5% | 29.7% |
| Mid Cap | 22.0% | 39.0% |
| Small Cap | 18.4% | 28.0% |
| Not on AMFI's list | 0.4% | 0.5% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Nippon India Banking & Financial Services | Nippon India Pharma |
|---|---|---|
| Pharmaceuticals & Biotechnology | 0.0% | 74.0% |
| Banks | 55.2% | 0.0% |
| Healthcare Services | 0.0% | 20.3% |
| Finance | 19.9% | 0.0% |
| Insurance | 11.2% | 0.0% |
| Capital Markets | 8.9% | 0.0% |
| Financial Technology (Fintech) | 4.0% | 0.0% |
| Retailing | 0.0% | 2.5% |
| Healthcare Equipment & Supplies | 0.0% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Nippon India Banking & Financial Services vs Nippon India Pharma: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Nippon India Banking & Financial Services Fund | Nippon India Pharma Fund |
|---|---|---|
| Total expense ratio (Direct) | 1.11% | 0.99% |
| Base expense ratio (Direct) | 0.83% | 0.79% |
| Total expense ratio (Regular) | 1.93% | 1.85% |
| Base expense ratio (Regular) | 1.54% | 1.52% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Nippon India Banking & Financial Services with
Nippon India Banking & Financial Services Fund vs Nippon India Pharma Fund: Frequently Asked Questions
What is the difference between Nippon India Banking & Financial Services Fund and Nippon India Pharma Fund?
Nippon India Banking & Financial Services Fund is a Sectoral fund, Nippon India Pharma Fund is a Sectoral fund, run by Nippon India Mutual Fund. Their portfolios overlap 0.0%. Nippon India Banking & Financial Services Fund charges 1.11% a year and Nippon India Pharma Fund 0.99%.
Which has given higher returns, Nippon India Banking & Financial Services Fund or Nippon India Pharma Fund?
Over 1 year: Nippon India Banking & Financial Services Fund −8.11%, Nippon India Pharma Fund +9.05%. Over 3 years: Nippon India Banking & Financial Services Fund +9.87% a year, Nippon India Pharma Fund +18.56% a year. Over 5 years: Nippon India Banking & Financial Services Fund +10.82% a year, Nippon India Pharma Fund +14.19% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Nippon India Banking & Financial Services Fund or Nippon India Pharma Fund?
Nippon India Pharma Fund charges less: 0.99% a year against 1.11%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Nippon India Banking & Financial Services Fund and Nippon India Pharma Fund overlap?
0.0%. They hold 0 of the same securities. From each fund's latest monthly portfolio.
Which is riskier, Nippon India Banking & Financial Services Fund or Nippon India Pharma Fund?
On SEBI's riskometer, Nippon India Banking & Financial Services Fund is rated Very High and Nippon India Pharma Fund Very High. Over 3 years, the standard deviation of daily returns was 15.26% and 12.96% a year.
Which is better for SIP, Nippon India Banking & Financial Services Fund or Nippon India Pharma Fund?
Over the last 5 years, a monthly SIP of ₹10,000 from 01-10-2021 to 30-10-2026 grew to ₹7,70,859 in Nippon India Banking & Financial Services Fund (XIRR 9.2% a year) and ₹9,14,295 in Nippon India Pharma Fund (XIRR 15.9% a year). Both received 61 instalments. Past returns do not promise future returns.
Can I invest in both Nippon India Banking & Financial Services Fund and Nippon India Pharma Fund?
Yes. 0.0% of each fund's money sits in the same holdings, so the two hold mostly different investments.
Who manages Nippon India Banking & Financial Services Fund and Nippon India Pharma Fund?
Nippon India Banking & Financial Services Fund: Vinay Sharma, Bhavik Dave. Nippon India Pharma Fund: Sailesh Raj Bhan.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.